Sequence generation {16a}
The study will be a randomized, open-label trial. Randomization will be implemented after all screening results are available for participants who have given informed consent and who have been found eligible for participation.Participants will be allocated using the Internet-Based Randomization service system: RANDOMIZE.NET. Participant randomization will be stratified by a bacterial load in sputum as measured by GeneXpert, cycle threshold (≥ 16, < 16), site (five sites have been activated: The Aurum site, Clinical HIV Research Unit (CHRU), KCRI/KIDH, the Ifakara site and the NIMR-MMRC site), and HIV status (positive, negative). Each site will have its own account and the allocation result will be generated by the web system immediately based on a minimization randomization algorithm. The minimization algorithm allocates the participant to the treatment arm with the lowest allocation proportion and includes a probabilistic element so that the allocation is not deterministic.